The price of VVOS is predicted to go up -38.1%, based on the high correlation periods with BNAI. The similarity of these two price pattern on the periods is 93.86%.
VVOS
BNAI
Down: -38.1%Similarity: 93.86%
VVOS Revenue Forecast
VVOS EPS Forecast
VVOS FAQs
What is bull’s view on VVOS?
VVOS stock closed at $3.97 on January 31, 2025, with a slight 1.02% gain during regular trading hours. The bullish view stems from its recent Zacks Rank #2 (Buy) upgrade, reflecting improved earnings estimates and potential investor interest. Analysts' price targets, such as $6.6 by Ascendiant Capital, suggest a significant upside of over 65% from the current price.
What is bear's view on VVOS?
VVOS stock faces bearish pressure due to the recent announcement of selling up to 854,332 shares by stockholders, which dilutes existing equity and limits upside potential. The stock closed at $3.97 on January 31, 2025, with a slight post-market decline to $3.94, reflecting cautious sentiment. Additionally, weak financial performance (-$1.79 EPS expected for FY 2024) and limited near-term catalysts further support a bearish outlook.
What is VVOS revenue forecast for next quarter?
The market consensus for VVOS's revenue in the upcoming quarter is projected to be approximately $4.1M USD.
What is VVOS eps forecast for next quarter?
The market consensus for VVOS's eps in the upcoming quarter is projected to be approximately $0.41 USD.
Alliance Global Partners analyst Scott Henry lowered the firm's price target on Vivos Therapeutics to $6 from $8.25 and keeps a Buy rating on the shares after the company reported Q3 earnings with results that were at the lower end of expectations. Results will take time to improve given the business model shift from dentists to sleep specialists, notes the firm, which expects "flattish results" in Q4 and lowered its revenue forecast for 2025.